OPGEN INC: insider trades · United States · SEC (Form 4)

About OPGEN INC

OpGen Inc. is a U.S.-based company that was originally built around molecular diagnostics and precision medicine, with a core mission of improving the detection of serious infectious diseases. Historically, the company developed and commercialized microbiology solutions designed to help hospitals and laboratories identify pathogens and antimicrobial resistance faster than traditional methods. Its product portfolio included the Unyvero systems and cartridges, as well as the Acuitas AMR product line and related testing solutions, with commercial reach in the United States and abroad. ([ir.opgen.com](https://ir.opgen.com/about-opgen/?utm_source=openai)) For investors, the key point is that OpGen has undergone a major strategic reset. In recent disclosures, the company stated that it had repositioned itself toward digital investment banking and financial technology through its newly formed subsidiary, CapForce International Holdings Ltd. That transformation is intended to support listing sponsorship and capital-markets services for growth-stage private companies, alongside plans for a next-generation digital investment banking platform with cross-border trading, AI-driven robo-advisory, asset-management functionality, and cap table management tools. In 2026, OpGen also advanced a corporate name change to CapForce Inc., underscoring that the business is no longer a pure-play diagnostics story. ([opgen.com](https://www.opgen.com/about-opgen/?utm_source=openai)) From a market perspective, OpGen had been listed on NASDAQ in the United States under the ticker OPGN, but the stock was later delisted and now trades on the OTC market. That change materially affects liquidity, trading visibility, governance expectations, and the investability profile for institutional and retail shareholders. Recent filings also highlight substantial doubt about the company’s ability to continue as a going concern, which is a critical consideration in any analysis of this name. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1293818/000182912625007819/opgeninc_10q.htm?utm_source=openai)) Historically, OpGen was founded as a diagnostics-focused company aimed at the faster identification of infectious disease threats, with a value proposition centered on antimicrobial stewardship and clinical decision support. Over time, however, the company faced severe operational and financial pressure, prompting it to shrink its commercial footprint, dispose of certain assets, and search for strategic alternatives. Recent transactions, including the sale of customer contracts and the installed base of Unyvero systems to Camtech, illustrate the scale of that rationalization process. The company has also relied on financing and restructuring steps to preserve optionality. ([ir.opgen.com](https://ir.opgen.com/news/opgen-provides-update-on-business-operations-and-strategic-opportunities/?utm_source=openai)) In summary, OpGen is now best understood as a U.S. corporate turnaround and transformation story rather than a traditional healthcare growth company. It remains a former NASDAQ-listed American issuer with a legacy diagnostics franchise, but the current narrative is centered on restructuring, corporate rebranding, and a push into fintech-related services. For French-speaking investors, the opportunity is highly speculative and comes with elevated execution risk, financing risk, and limited operational visibility. ([opgen.com](https://www.opgen.com/about-opgen/?utm_source=openai))